#EULAR2022 LB0005 Orelabrutinib- BTKi- for SLE, PIb/IIa ⭐️Improved SRI-4 and SLEDAI-2K vs PBO, dose response for SRI-4 ⭐️Improved proteinuria @Rheumnow https://t.co/bmREhmL7sq

Another possible Rx for #SLE: Phase Ib/IIa orelabrutinib (irrevers BTKi) for SLE shows promise. Improvement in SRI-4, SLEDAI2K, proteinuria, dsDNA, C3/C4; dec in IgG/M/Bcells. Safety: lymphopenia w/ORE #EULAR2022 LB0005 @rheumnow https://t.co/etZ9hMYNfn

Orelabrutinib Bruton’s tyrosine kinase inhibitor in SLE RCT phase Ib/IIa SRI(4) wk 12 50mg 50% 80mg 61% and 100mg 64% and 37.5% PBO Trend ⬇️ proteinuria, anti-dsDNA & IgG Safety: 3SAEs in OLE group LB0005 @RheumNow #EULAR2022 https://t.co/4r16NTaZvT

@EricFMorand up first in late-breakings PAISLEY: deucravacitinib (TYK2i) ph2 in SLE - add-on, steroid wean Good outcomes: primary: SRI(4) at 32w skin/joint/LLDAS & dsDNA/C4 Safety good (like PsO/PsA) but higher dose less so Watch for: other clinical, ph3 #EULAR2022 @RheumNow https://t.co/XOQWuiHkTx

Wow! Phase 2 #deucravacitinib data for #SLE met primary & secondary endpoints: SRI(4) response, BICLA, LLDAS, CLASI-50. AEs include: skin related events and UTIs but no increase in SIE, HZ, MACE/VTE @bmsnews LB0004 #EULAR022 @rheumnow https://t.co/bsKI0mixVT

#POS1236 #EULAR2022 More data to justify safety of #COVID vaccination to our #lupus patients. A study in Italy (>450 pts) found 1/4 had side effects (mostly mild) and 4% had a flare. These side effects were more common in those on >1 DMARDS and Belimumab @RheumNow https://t.co/mNS6rQfsSq

Morand et al Tyk2i deucravacitinib in SLE. 48-week phase 2 RCT. SRI(4) PBO: 34.4%; DEUC 3 mg BID: 58.2%, P =0.0006; DEUC 6 mg BID: 49.5%, P =0.021; DEUC 12 mg QD: 44.9%, P =0.078. BICLA, LLDAS, CLASI-50, active joint count also+ @RheumNow #EULAR2022 LB0004 https://t.co/MBPc9xQFvG https://t.co/n3GUwl0RtD

• EULAR Abstract Archive

PAISLEY LB004 @EricFMorand on deucravacitinib phase 2 for SLE ⭐️Meets primary endpt: SRI(4) ⭐️Secondary endpts: BICLA, LLD, CLASI, jt count, biomarkers improved ⭐️Safety data wo VTE, CVD events Earlier at #EULAR2022, BRAVE trial phase 3 baricitinib: No benefit in SLE @RheumNow https://t.co/3YpPSJcenF

PAISLEY study Phase 2 RCT Deucravacitinib in SLE meets primary endpoint wk 32 Results for dose 3mg BID: *SRI(4) response 58.2% vs. PBO 34% *LLDAS 36% *CLASI 70% *⬇️ SJC No new safety signal Now waiting for Phase 3 👀 @RheumNow LB0004 #EULAR2022 #Lupus https://t.co/2KYSvfq4h7

Please see my video interview with Dr @LucyCarter6 on her prize winning #EULAR2022 abstract #OP0234 on transcriptomic analyses of peripheral bloods in identifying modules that predict OR protect progression from ANA+ to #lupus or CTD @RheumNow https://t.co/c3khwFzx79

• Dr. Lucy Carter on RNA-Seq analysis to determine who's at risk for SLE - Yo…